Search Results Search Sort by RelevanceMost Recent State of the Art and Science Nov 2019 What’s Missing in Our Thinking About Quality of Life in VCA? Emily Herrington, PhD, MA Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported. AMA J Ethics. 2019;21(11):E968-973. doi: 10.1001/amajethics.2019.968. State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412. State of the Art and Science Nov 2004 Chronic Myeloid Leukemia and the Application of Rational Drug Design Richard Maury Stone, MD Imatinib is a pharmaceutical therapy recently approved by the FDA to help treat chronic myeloid leukemia. Virtual Mentor. 2004;6(11):497-500. doi: 10.1001/virtualmentor.2004.6.11.cprl1-0411. Pagination First page « First Previous page ‹ Previous Page 1 Current page 2
State of the Art and Science Nov 2019 What’s Missing in Our Thinking About Quality of Life in VCA? Emily Herrington, PhD, MA Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported. AMA J Ethics. 2019;21(11):E968-973. doi: 10.1001/amajethics.2019.968.
State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412.
State of the Art and Science Nov 2004 Chronic Myeloid Leukemia and the Application of Rational Drug Design Richard Maury Stone, MD Imatinib is a pharmaceutical therapy recently approved by the FDA to help treat chronic myeloid leukemia. Virtual Mentor. 2004;6(11):497-500. doi: 10.1001/virtualmentor.2004.6.11.cprl1-0411.